Key facts
- This page summarizes Bios 2024 Co-Invest, LP's Form 3 filing for ACTUATE THERAPEUTICS, INC. (ACTU).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 14 Aug 2024, 19:48.
Bios 2024 Co-Invest, LP - 14 Aug 2024 Form 3 Insider Report for ACTUATE THERAPEUTICS, INC. (ACTU)
- Reporting relationship
- Director, Member of 10% Group
- Issuer ticker
- ACTU
- Reported as of
- 14 Aug 2024
- Net transaction value
- $0
- Reporting owner signature
- Bios 2024 Co-Invest, LP By: Bios Equity COF, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ Aaron Glenn Louis Fletcher, Manager
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Bios 2024 Co-Invest, LP filed Form 3 for ACTUATE THERAPEUTICS, INC. (ACTU) on 14 Aug 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACTU
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 125,000
- Date
- 14 Aug 2024
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
This Form 3 is being filed by Bios 2024 Co-Invest, LP to reflect their admission as members into the "group" (for Section 13 and Section 16 purposes) previously composed of Bios Fund I, LP, Bios Fund I QP, LP, Bios Fund II, LP, Bios Fund II QP, LP, Bios Fund II NT, LP, Bios Fund III, LP, Bios Fund III QP, LP, Bios Fund III NT, LP, BP Directors, LP, Bios Actuate Co-Invest I, LP, Bios Actuate Co-Invest II, LP, Bios Acuate Co-Invest III, LP, Bios Clinical Opportunity Fund, LP, Bios Equity Partners III, LP, Bios Equity Partners II, LP, Bios Equity Partners, LP, Bios Equity COF, LP, Bios Capital Management, LP, Cavu Management, LP, Bios Advisors GP, LLC, Cavu Advisors, LLC, Aaron G.L. Fletcher and Leslie W. Kreis. The reporting person may be deemed to be a "director by deputization" as the result of Aaron G.L. Fletcher's position as a director of the issuer. Exhibit 24 - Power of Attorney